The investment marks the first time MY DR NOW has received external capital.
After a long and complex prenotification phase before the European Commission, Orrick obtained an early unconditional clearance of the transaction.
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
Returning investor OMERS Growth Equity led the round, which also included Fidelity Management & Research Company and other current investors.
ESG factors are increasingly important in the life sciences. Managing ESG risks and opportunities can be an important source of long-term value.
The last year has seen a multijurisdictional regulatory push for increased cybersecurity standards for medical devices. Here's what you need to know.
Two of our partners and an Andersen director author Law360 article on tax implications in LSC collaboration deals.
by Franklin Monsour Jr. | September.19.2022
Franklin Monsour posted this article on Law360 on taking more FCA cases to trial.
by Thora Johnson | August.10.2022
EU & US Privacy and Security Considerations for Covid-19 Data Processing Activities From Pandemic to Living with Covid written by Thora Johnson.
Our lawyers wrote Newsweek opinion piece calling for federal legislation to address privacy vulnerabilities after Dobbs.
Congratulations to Orrick partner Gregg Griner on being recognized as a Go-To Lawyer for Healthcare and Life Sciences by Massachusetts Lawyers Weekly.
Orrick welcomes Franklin Monsour, a former federal prosecutor and experienced white collar and regulatory adviser to the life sciences sector.